 Cullinan Oncology Inc NASDAQ: CGEM reported updated data from its ongoing Phase 12a trial of CLN-081 in non-small cell lung cancer NSCLC patients. The trial includes patients whose tumors harbor epidermal growth factor receptor EGFR exon 20 insertion mutations that have progressed on or after prior therapy. 